There is a growing body of research into the therapeutic use of psilocybin, MDMA, and other entheogens, and it is inspiring policymakers, medical experts, and the public to reexamine drug policy at every level of government. Vicente Sederberg is committed to working with communities to develop sensible policy solutions that advance the public interest.
Vicente Sederberg has specialized in cannabis policy for over a decade, and we understand the complexities of transitioning a controlled substance from a prohibition model to a more nuanced system, in which it is decriminalized or regulated for research and other legal purposes. Our attorneys have extensive experience shaping decriminalization and regulatory policies in the U.S. and internationally, helping businesses, governments, advocates, and others understand and tactically navigate the interplay between local, state, and federal laws.
Laws, legal authorities, and avenues for reform vary from city to city and state to state, so we help our clients craft and execute impactful strategies and policy reform movements tailored to the unique legal and political considerations that apply in each jurisdiction. We also maintain strategic relationships with firms that have extensive experience navigating the complex federal and state regulatory landscapes surrounding the development of novel and emerging therapeutic products. Most notably, VS has formed an alliance with Kleinfeld, Kaplan & Becker LLP, a Washington, D.C.-based firm that concentrates on the regulation of products subject to the jurisdiction of the U.S. Food and Drug Administration (FDA) — including drugs and biologics, medical devices, dietary supplements, and controlled substances — as well as advertising law and other regulatory law governing consumer products and services. See the "Services" tab below for more details.